Z Kopeikin1, Z Yuksek1, H-Y Yang2, S G Bompadre3. 1. Department of Physics and Astronomy, University of Missouri, Columbia, MO 65211, USA; Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA. 2. Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA. 3. Department of Physics and Astronomy, University of Missouri, Columbia, MO 65211, USA; Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA. Electronic address: BompadreS@missouri.edu.
Abstract
BACKGROUND: The most common cystic fibrosis-associated mutation, the deletion of phenylalanine 508 (F508del), results in channels with poor membrane expression and impaired function. VX-770, a clinically approved drug for treatment of CF patients carrying the G551D mutation, and VX-809, a corrector shown in vitro to increase membrane expression of mutant channels, are currently undergoing clinical trials, but functional data at the molecular level is still lacking. METHODS: The effect of VX-770 and VX-809 on the multiple functional defects of F508del-CFTR was assessed via excised inside-out patch-clamp experiments. RESULTS: VX-770 completely restores the low opening-rate of F508del-CFTR, with smaller open-time increase, in temperature-corrected and VX-809-treated channels. The shorter locked-open time of hydrolysis-deficient F508del-CFTR is also prolonged by VX-770. VX-809 does not improve channel function by itself as previously reported. CONCLUSIONS: The results from these studies can be interpreted as an equilibrium shift toward the open-channel conformation of F508del-CFTR channels.
BACKGROUND: The most common cystic fibrosis-associated mutation, the deletion of phenylalanine 508 (F508del), results in channels with poor membrane expression and impaired function. VX-770, a clinically approved drug for treatment of CFpatients carrying the G551D mutation, and VX-809, a corrector shown in vitro to increase membrane expression of mutant channels, are currently undergoing clinical trials, but functional data at the molecular level is still lacking. METHODS: The effect of VX-770 and VX-809 on the multiple functional defects of F508del-CFTR was assessed via excised inside-out patch-clamp experiments. RESULTS:VX-770 completely restores the low opening-rate of F508del-CFTR, with smaller open-time increase, in temperature-corrected and VX-809-treated channels. The shorter locked-open time of hydrolysis-deficient F508del-CFTR is also prolonged by VX-770. VX-809 does not improve channel function by itself as previously reported. CONCLUSIONS: The results from these studies can be interpreted as an equilibrium shift toward the open-channel conformation of F508del-CFTR channels.
Authors: Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard Journal: Br J Pharmacol Date: 2018-02-22 Impact factor: 8.739
Authors: Alison E Fohner; Ellen M McDonagh; John P Clancy; Michelle Whirl Carrillo; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2017-01 Impact factor: 2.089
Authors: Long Ye; Bao Hu; Faris El-Badri; Brandi M Hudson; Puay-Wah Phuan; A S Verkman; Dean J Tantillo; Mark J Kurth Journal: Bioorg Med Chem Lett Date: 2014-10-02 Impact factor: 2.823